HGF attracts IP strategy expert from global pharmaceutical giant
HGF is delighted to announce the arrival of Mike Nelson from a senior position at AstraZeneca to further strengthen its offering within the pharmaceuticals and chemistry teams.
Mike’s extensive pharmaceutical experience further strengthens the existing pharmaceutical team, one of the largest in Europe. Their combined specialisms cover not only all the core technology areas such as new chemical entities, formulations, drug delivery, methods of treatment, salts and crystalline forms, but also the broader commercial and lifecycle management space, including data exclusivity and patent term extension such as SPCs. Mike is able to draw on his broad experiences to provide clients with commercially focussed and pragmatic patent and business development strategies, including portfolio review, due diligence and licensing. Jonathan Couchman commented:
“We are delighted to have Mike Nelson join our office. He has a wealth of commercial experience and his knowledge and skills base will further enhance the firm’s offering”.
He further commented: “We have further strengthened HGF’s position as one of the top IP firms in the country across all business sectors. The HGF pharma team has already been extremely successful in gaining clients nationally and internationally. In pharmaceuticals, we are one of a few European IP firms able to provide high level commercial and technical excellence to the industry, and with Mike Nelson we can build further on this existing platform, especially in commercial strategy”.
Mike Nelson said: “HGF is currently one of the fastest growing intellectual property specialists in the UK. This growth stems from its proactive approach and understanding of its client’s business needs. Together with the considerable technical expertise and industrial experience of its attorneys, HGF provides clients with an unrivalled intellectual property service. I am delighted to be joining a leading European pharmaceuticals IP group and am looking forward to contributing to the firm’s continued growth as it confirms its position as a leader in the intellectual property market”.